Tear Film Innovations, Inc., a San Diego, CA-based early-stage company developing products for the treatment of evaporative dry eye and related syndromes including Meibomian Gland Dysfunction (MGD) and blepharitis, completed a $9m Series A funding.
The round was led by Visionary Ventures Fund, L.P. and Tigris Ventures, LLC.
The company intends to use the funds to continue to develop its evaporative dry eye treatment system through regulatory approvals to commercialization.
Led by Rob Thornhill, CEO and President, TFI is advancing the iLux® system, an investigational device currently under review by the U.S. Food and Drug Administration. The device enables eye care professionals to provide in-office treatment of blocked meibomian glands through targeted heating and compression of affected eyelids.
TFI recently completed a multi-site clinical study demonstrating the safety and efficacy of the system.